Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stellest Lenses and Low-concentration Atropine Myopia Control Among Children
Sponsor: Essilor-Polylite Taiwan Co., Ltd.
Summary
The prevalence of myopia is increasing globally, especially in Asian countries. 70-80% of the young population suffers from myopia, and almost 20% have high myopia. High myopia can easily lead to blinding diseases, including retinal detachment, macular degeneration, and glaucoma. In Taiwan, according to a survey by the National Health Administration, the proportion of myopia among Grade 1 students has exceeded 81%. There are many ways to control myopia progression. High concentrations of atropine have been reported highly effective in the control of the myopia progression. However the accompanied side effects such as photophobia and near blurred vision. Recent research shows that low-concentration atropine can achieve similar control effect and more acceptable with much minimal side effect compared to high concentration of atropine. Multiple animal experiments have confirmed that giving retinal myopia defocus signals can effectively decrease the growth of the eye, thereby inhibiting the progression of myopia. Therefore, regarding lens design, myopic defocus does play an important role in myopia control, including orthokeratology lenses, multifocal soft contact lenses, and peripheral defocus lenses. Stellest, a myopia control lens based on the myopia defocus theory, is equipped with highly aspheric lenslet technology. In a recent study, compared with single vision lenses, Stellest significantly slowed down the myopia progression reaching 67% and retard axial elongation reaching 64% The purpose of this study is to explore the effectiveness of Stellest Lenses in controlling myopia in Taiwanese children and whether Stellest Lenses combined with low-concentration atropine eye drops can increase the effect of myopia control.
Official title: Exploring the Effects of Treatment With Stellest Lenses and Low-concentration Atropine for Myopia Control Among Children.
Key Details
Gender
All
Age Range
6 Years - 12 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-08-20
Completion Date
2025-08-20
Last Updated
2024-04-04
Healthy Volunteers
Yes
Conditions
Interventions
Stellest Lenses
All subjects are recruited and randomized to 3 treatment groups at the baseline visit. A Group：Stellest Lenses spectacle (ST)
Stellest Lenses+0.05% atropine
All subjects are recruited and randomized to 3 treatment groups at the baseline visit. B Group：Combined Treatment
Single vision Lenses+0.05% atropine
All subjects are recruited and randomized to 3 treatment groups at the baseline visit. C Group：0.05% Atropine with single vision
Locations (1)
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan